Cited by 490Schizophrenia research and treatmentPharmacology and Obesity TreatmentEating Disorders and Behaviors

The DOI matches its Crossref record; 363 of the 363 references it cites were found in a registry or an index.

Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis

Open access

Bak, Maarten, Fransen, Annemarie, Janssen, Jouke, van Os, Jim, Drukker, Marjan·2014·PLoS ONE

DOI 10.1371/journal.pone.0094112PMC PMC3998960

Open this paper in CoChat — free account Open PDF

Abstract

INTRODUCTION: Antipsychotics (AP) induce weight gain. However, reviews and meta-analyses generally are restricted to second generation antipsychotics (SGA) and do not stratify for duration of AP use. It is hypothesised that patients gain more weight if duration of AP use is longer. METHOD: A meta-analysis was conducted of clinical trials of AP that reported weight change. Outcome measures were body weight change, change in BMI and clinically relevant weight change (7% weight gain or loss). Duration of AP-use was stratified as follows: ≤6 weeks, 6-16 weeks, 16-38 weeks and >38 weeks. Forest plots stratified by AP as well as by duration of use were generated and results were summarised in figures. RESULTS: 307 articles met inclusion criteria. The majority were AP switch studies. Almost all AP showed a degree of weight gain after prolonged use, except for amisulpride, aripiprazole and ziprasidone, for which prolonged exposure resulted in negligible weight change. The level of weight gain per AP varied from discrete to severe. Contrary to expectations, switch of AP did not result in weight loss for amisulpride, aripiprazole or ziprasidone. In AP-naive patients, weight gain was much more pronounced for all AP. CONCLUSION: Given prolonged exposure, virtually all AP are associated with weight gain. The rational of switching AP to achieve weight reduction may be overrated. In AP-naive patients, weight gain is more pronounced.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0094112

Cites

363 of 363 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Items 201–363 of 363

Weight Gain and Antipsychotic Medication
Simpson, M. M., Goetz, R. R., Devlin, M. J., Goetz, S. A., & Walsh, B. T. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0906 · Cited by 63 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effect of overweight on gastrointestinal microbiology and immunology: correlation with blood biomarkers
Tiihonen, K., Ouwehand, A. C., & Rautonen, N. (2009) · British Journal Of Nutrition · doi:10.1017/s0007114509992807 · Cited by 63 · cited 7×
“Long term use of antipsychotics (AP) is associated with increased mortality risk in people with SMI [16,17].”
BackgroundInfluential
Weight Gain With Clozapine Compared to First Generation Antipsychotic Medications
Covell, N. H., Weissman, E. M., & Essock, S. M. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007074 · Cited by 62 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Randomized, 1-Year Follow-up Study of Olanzapine and Risperidone in the Treatment of Negative Symptoms in Outpatients with Schizophrenia
Álvarez, E., Ciudad, A., Olivares, J. M., Bousoño, M., & Gómez, J. C. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000222513.63767.de · Cited by 62
A 24-Week, Multicenter, Open-Label, Randomized Study to Compare Changes in Glucose Metabolism in Patients With Schizophrenia Receiving Treatment With Olanzapine, Quetiapine, or Risperidone
Newcomer, J. W., Ratner, R. E., Eriksson, J. W., Emsley, R. A., Meulien, D., Miller, F., Leonova-Edlund, J., Leong, R. W., & Brecher, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04132 · Cited by 62 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Therapeutic Tolerance and Rebound Psychosis During Quetiapine Maintenance Monotherapy in Patients With Schizophrenia and Schizoaffective Disorder
Margolese, H. C., Chouinard, G., Beauclair, L., & Bélanger, M.-C. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00003 · Cited by 61 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine Versus Aripiprazole for the Treatment of Agitation in Acutely Ill Patients With Schizophrenia
Kinon, B. J., Stauffer, V. L., Kollack‐Walker, S., Chen, L., & Sniadecki, J. L. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818aaf6c · Cited by 61 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine Versus Placebo in Acute Mania
Baldessarini, R. J., Hennen, J. A., Wilson, M., Calabrese, J. R., Chengappa, R., Keck, P. E., McElroy, S. L., Sachs, G. S., Vieta, E., Welge, J. A., et al. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085410.08426.9a · Cited by 61 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
The cumulative needs for care monitor: a unique monitoring system in the south of the Netherlands
Drukker, M., Bak, M., Campo, J. Á., Driessen, G., van Os, J., & Delespaul, P. (2009) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-009-0088-3 · Cited by 61 · cited 1×
“r was estimated using data from a local longitudinal register of medication use in relation to somatic parameters [38] (data available July 2006–September 2012) as follows: weight change R6–16 weeks: 0.”
MethodSelf-citation
Contributing factors to weight gain during long‐term treatment with second‐generation antipsychotics. A systematic appraisal and clinical implications
Gentile, S. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00589.x · Cited by 61 · cited 1×
“Particularly clozapine and olanzapine were associated with severe weight gain, whereas aripiprazole and ziprasidone appeared almost weight neutral [5,20,23,24,26–31].”
Background
Changes in Neuroendocrine and Metabolic Hormones Induced by Atypical Antipsychotics in Normal-Weight Patients with Schizophrenia
POPOVIC, V. M., Doknić, M., Marić, N. P., Pekić, S., Damjanović, A., Miljić, D., Popović, S., Miljic, N., Djurovic, M. N., Jašović‐Gašić, M., et al. (2007) · Neuroendocrinology · doi:10.1159/000103868 · Cited by 60 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Risk of Weight Gain Associated with Antipsychotic Treatment: Results from the Canadian National Outcomes Measurement Study in Schizophrenia
McIntyre, R. S., Trakas, K., Lin, D., Balshaw, R. F., Hwang, P., Robinson, K. A., & Eggleston, A. (2003) · The Canadian Journal of Psychiatry · doi:10.1177/070674370304801008 · Cited by 59 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine in Refractory Schizophrenia After Failure of Typical or Atypical Antipsychotic Treatment
Lindenmayer, J., Czobor, P., Volavka, J., Lieberman, J. A., Citrome, L., Sheitman, B., Chakos, M., & McEvoy, J. P. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1011 · Cited by 59 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic
Ascher‐Svanum, H., Stensland, M. D., Kinon, B. J., & Tollefson, G. D. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105058978 · Cited by 59 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Potential effectiveness and safety of olanzapine in refractory panic disorder
Hollifield, M., Thompson, P. M., Ruiz, J. E., & Uhlenhuth, E. H. (2005) · Depression and Anxiety · doi:10.1002/da.20050 · Cited by 58 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Weight decline in patients switching from olanzapine to quetiapine
Gupta, S., Masand, P. S., Virk, S., Schwartz, T. L., Hameed, A., Frank, B. L., & Lockwood, K. (2003) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.016 · Cited by 58 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: Results from a six-month prospective, multinational, observational study
Treuer, T., Hoffmann, V. P., Chen, A. K.-P., Irimia, V., Ocampo, M., Wang, G., Singh, P., & Holt, S. H. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970903079507 · Cited by 58 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Open-Label Study of Atypical Neuroleptic Quetiapine for Treatment of Borderline Personality Disorder
Villeneuve, É., & Lemelin, S. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1013 · Cited by 57 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects
Graham, K. A., Cho, H., Brownley, K. A., & Harp, J. B. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.476 · Cited by 57 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine Treatment of Residual Positive and Negative Symptoms
Buchanan, R. W., Ball, M. P., Weiner, E., Kirkpatrick, B. W., Gold, J. M., McMahon, R. P., & Carpenter, W. T. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.124 · Cited by 57 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods
Kinon, B. J., Jeste, D. V., Kollack‐Walker, S., Stauffer, V. L., & Liu‐Seifert, H. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.05.016 · Cited by 56 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations
Llorca, P., Lançon, C., Disdier, B., Farisse, J., Sapin, C., & Auquier, P. (2002) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0203 · Cited by 55 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Metabolic Issues in Patients with Severe Mental Illness
Citrome, L., Blonde, L., & Damatarca, C. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000167621.49292.11 · Cited by 55 · cited 1×
“Particularly clozapine and olanzapine were associated with severe weight gain, whereas aripiprazole and ziprasidone appeared almost weight neutral [5,20,23,24,26–31].”
Background
The Association of Weight Gain and Olanzapine Plasma Concentrations
Perry, P. J., Argo, T. R., Carnahan, R. M., Lund, B. C., Holman, T. L., Ellingrod, V. L., & Miller, D. D. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000162800.64378.82 · Cited by 55 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effects of Patient Demographics, Risperidone Dosage, and Clinical Outcome on Body Weight in Acutely Exacerbated Schizophrenia
Lane, H., Chang, Y., Cheng, Y.-C., Liu, G.-C., Lin, X.-R., & Chang, W. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0314 · Cited by 55 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effects of Olanzapine and Risperidone on Glucose Metabolism and Insulin Sensitivity in Chronic Schizophrenic Patients With Long-Term Antipsychotic Treatment
Smith, R. C., Lindenmayer, J., Davis, J. M., Kelly, E., Viviano, T. F., Cornwell, J., Hu, Q., Khan, A., & Vaidhyanathaswamy, S. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04446yel · Cited by 55 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder
Potkin, S. G., Ogasa, M., Cucchiaro, J. B., & Loebel, A. D. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.008 · Cited by 55 · cited 1×
“9 kg (,6 wk, n = 90) [47], pimozide 2.”
Aripiprazole Therapy in 20 Older Adults With Bipolar Disorder
Sajatovic, M., Coconcea, N., Ignacio, R. V., Blow, F. C., Hays, R. W., Cassidy, K. A., & Meyer, W. J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0106 · Cited by 54
A Double-blind, Randomised Comparative Trial of Amisulpride Versus Olanzapine in the Treatment of Schizophrenia: Short-term Results at Two Months
Martin, S. D., Löo, H., Peuskens, J., Thirumalai, S., Giudicelli, A., Fleurot, O., Rein, W., & for the SOLIANOL Study Group (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125001128 · Cited by 54
Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia
Kelly, D. L., Conley, R. R., Richardson, C. M., Tamminga, C. A., & Carpenter, W. T. (2003) · Annals of Clinical Psychiatry · doi:10.1023/b:acli.0000008171.90644.f8 · Cited by 53 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Weight Gain, Schizophrenia and Antipsychotics: New Findings from Animal Model and Pharmacogenomic Studies
Panariello, F., Luca, V. D., & de Bartolomeis, A. (2010) · Schizophrenia Research and Treatment · doi:10.1155/2011/459284 · Cited by 53
Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study
Muzina, D. J., Momah, C., Eudicone, J. M., Pikalov, A., McQuade, R. D., Marcus, R. N., Sanchez, R., & Carlson, B. X. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01735.x · Cited by 52 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study
Pae, C., Serretti, A., Chiesa, A., Mandelli, L., Lee, C., Lee, C., Kim, J., Ronchi, D. D., & Paik, I. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.04.002 · Cited by 52 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Switching Antipsychotic Medications to Reduce Adverse Event Burden in Schizophrenia: Establishing Evidence-Based Practice
Newcomer, J. W., Weiden, P. J., & Buchanan, R. W. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12028ah1 · Cited by 51 · cited 3×
“Psychiatrists should keep in mind that switching antipsychotics requires monitoring and evaluation [51] and may benefit from concurrent non-pharmacological interventions [58,59].”
Background
Antipsychotic-Induced Weight Gain: Bipolar Disorder and Leptin
McIntyre, R. S., Mancini, D. A., Basile, V. S., Srinivasan, J., & Kennedy, S. H. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085403.08426.f4 · Cited by 50 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of second-generation antipsychotics with acute-phase schizophrenia
Hatta, K., Sato, K., Hamakawa, H., Takebayashi, H., Kimura, N., Ochi, S., Sudo, Y., Asukai, N., Nakamura, H., Usui, C., et al. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.030 · Cited by 50
Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia
Riedel, M. J., Müller, N., Spellmann, I., Engel, R. R., Musil, R., Valdevit, R., Dehning, S., Douhet, A., Cerovecki, A., Strassnig, M., et al. (2007) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0748-9 · Cited by 50 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study
ZIMBROFF, D. L., Warrington, L. E., Loebel, A. D., Yang, R., & SIU, C. O. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32816f7779 · Cited by 49 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder
Lasser, R. A., Bossie, C. A., Gharabawi, G. M., Eerdekens, M., & Nasrallah, H. A. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.05.008 · Cited by 49 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A 6-Month Prospective Observational Study on the Effects of Quetiapine on Sexual Functioning
Montejo, A. L., Rico‐Villademoros, F., Tafalla, M., & Majadas, S. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000186872.04984.56 · Cited by 48
The Effect of a Switch to Ziprasidone in an Adult Population With Autistic Disorder
Cohen, S. A., Fitzgerald, B. J., Khan, S., & Khan, A. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0119 · Cited by 48 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia
Ader, M., Garvey, W. T., Phillips, L. S., Nemeroff, C. B., Gharabawi, G. M., Mahmoud, R. A., Greenspan, A. J., Berry, S. A., Musselman, D. L., Morein, J., et al. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.01.004 · Cited by 48 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Weight Gain During Treatment of Bipolar I Patients With Olanzapine
Hennen, J. A., Perlis, R. H., Sachs, G. S., Tohen, M. F., & Baldessarini, R. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1214 · Cited by 48 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia
Azorin, J., Strub, N., & Loft, H. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000177020.26311.a7 · Cited by 48
Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone
Canuso, C. M., Youssef, E. A., Bossie, C. A., Turkoz, I., Schreiner, A., & Simpson, G. M. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282fce651 · Cited by 48 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study
Gasquet, I., Haro, J. M., Novick, D., Edgell, E. T., Kennedy, L., & Lepine, J. P. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200507000-00002 · Cited by 48 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics.
Meltzer, H. Y. (2001) · PubMed · Cited by 47
Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database
Bushe, C., Slooff, C. J., Haddad, P. M., & Karagianis, J. L. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112473789 · Cited by 47 · cited 1×
“5) levels [57].”
Comparing the Safety and Efficacy of Atypical Antipsychotics in Psychiatric Patients With Comorbid Medical Illnesses
Newcomer, J. W. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.7075su1c.05 · Cited by 47 · cited 1×
“In general, it is concluded that AP add to the increased mortality risk of people with SMI either through direct cardio toxic effects or by impacting on weight gain [8,18].”
Background
The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine
Chiu, C.-C., Chen, C.-H., Chen, B.-Y., Yu, S.-H., & Lu, M. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.04.003 · Cited by 47 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Randomized, Double-Blind, Placebo-Controlled Trial of Long-Acting Risperidone in Cocaine-Dependent Men
Loebl, T., Angarita, G. A., Pachas, G. N., Huang, K., Lee, S. H., Nino, J., Logvineko, T., Maravić, M. C., & Evins, A. E. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0321 · Cited by 46 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis.
Leelahanaj, T., Kongsakon, R., & Netrakom, P. (2005) · PubMed · Cited by 45
Cognitive impairment in elderly patients with schizophrenia: age related changes
Harvey, P. D. (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/1099-1166(200112)16:1+ · Cited by 44
Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder
Lindenmayer, J., Khan, A., Eerdekens, M., Hove, I. V., & Kushner, S. F. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.08.004 · Cited by 43
Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine
Gastpar, M., Masiak, M., Latif, M. A., Frazzingaro, S., Medori, R., & Lombertie, E. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056598 · Cited by 42 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Double-Blind, Randomized Study Comparing the Efficacy and Safety of Sertindole and Risperidone in Patients With Treatment-Resistant Schizophrenia
Kane, J. M., Potkin, S. G., Daniel, D. G., & Buckley, P. F. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03733yel · Cited by 42 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia
Baptista, T., Dávila, A., Fakih, Y. E., Uzcátegui, E., Rangel, N., Olivares, Y., Galeazzi, T., Vargas, D., Peña, R., Marquina, D., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328080ca44 · Cited by 42 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study
Alptekın, K., Hafez, J., Brook, S., Akkaya, C., Tzebelikos, E., Üçok, A., tallawy, H. E., DANACI, A. E., Lowe, W., & Karayal, O. N. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832c2624 · Cited by 41 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients
Barak, Y., Shamir, E. Z., Zemishlani, H., Mirecki, I., Toren, P., & Weizman, R. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00322-0 · Cited by 41 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Quality of Life in Schizophrenia
de Lima, M. S., Mari, J. D. J., Breier, A. F., Costa, A., de Sena, E. P., & Hotopf, M. H. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0704 · Cited by 41
Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets
de Haan, L., van Amelsvoort, T., Rosien, K., & LINSZEN, D. H. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1951-2 · Cited by 41 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study
Sacchetti, E., Galluzzo, A., Valsecchi, P., Romeo, F., Gorini, B., & Warrington, L. E. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.002 · Cited by 41 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Switching to Olanzapine From Previous Antipsychotics
Lee, C., Conde, B. J. L., Mazlan, M., Visanuyothin, T., Wang, A., Wong, M. M. C., Walker, D. J., Roychowdhury, S. M., Wang, H., & Trân, P. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0706 · Cited by 38 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
No Weight Gain Among Elderly Schizophrenia Patients After 1 Year of Risperidone Treatment
Barak, Y. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0205 · Cited by 38 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study
Haro, J. M., Novick, D., Suarez, D. L., & Roca, M. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.06.001 · Cited by 38 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: A randomized, open-label, controlled trial
Kim, S., Shin, I., Kim, J., Lee, S.-H., Lee, J., Yoon, B.-H., Yang, S., Hwang, M. Y., & Yoon, J. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.005 · Cited by 37 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes
Sevy, S. M., Robinson, D. G., Sunday, S. R., Napolitano, B. A., Miller, R., McCormack, J., & Kane, J. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2011.05.001 · Cited by 37 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effects of switching to long‐acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia
Kim, S., Shin, I., Kim, J., Lee, S., Lee, Y., Yang, S., & Yoon, J. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1057 · Cited by 37 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12‐week observational study
Strous, R. D., Kupchik, M., Roitman, S., Schwartz, S., Gonen, N., Mester, R., Weizman, A., & Spivak, B. (2006) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.764 · Cited by 37
Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients
Malempati, R. N., Bond, D. J., & Yatham, L. N. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2b4c5 · Cited by 37 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first‐episode never treated psychotic patients
Arranz, B., San, L., Dueñas, R., Centeno, M., Ramírez, N. D., Salavert, J., & del Moral, E. (2006) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.819 · Cited by 37 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
The Moderating Impact of Ethnicity on Metabolic Outcomes During Treatment With Olanzapine and Aripiprazole in Patients With Schizophrenia
Meyer, J. M., Rosenblatt, L. C., Kim, E., Baker, R. A., & Whitehead, R. E. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04267 · Cited by 37 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Randomized, Double-Blind, Parallel-Group, Fixed-Dose, Clinical Trial of Quetiapine at 600 Versus 1200 mg/d for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder
Lindenmayer, J., Citrome, L., Khan, A., Kaushik, S., & Kaushik, S. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820f4fe0 · Cited by 37
A Review and Bayesian Meta-Analysis of Clinical Efficacy and Adverse Effects of 4 Atypical Neuroleptic Drugs Compared With Haloperidol and Placebo
Klemp, M., Tvete, I. F., Skomedal, T., Gåsemyr, J., Natvig, B., & Aursnes, I. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823657d9 · Cited by 36 · cited 1×
“Subsequent metaanalyses confirmed the finding that most AP contributes to weight gain [20–26].”
Olanzapine for Schizophrenia Refractory to Typical and Atypical Antipsychotics: An Open-Label, Prospective Trial
Lindenmayer, J., Volavka, J., Lieberman, J. A., Sheitman, B., Citrome, L., Chakos, M., Czobor, P., Parker, B., & Iskander, A. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00014 · Cited by 36 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine
Peuskens, J., Binder, M. D., & Mortimer, A. M. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3280148c29 · Cited by 35 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Long-acting risperidone in stable patients with schizoaffective disorder
Mohl, A., Westlye, K., Opjordsmoen, S., Lex, A., Schreiner, A., Benoît, M., Bräunig, P., & Medori, R. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056515 · Cited by 35
A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression
Vanelle, J., & Douki, S. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2006.09.003 · Cited by 35
Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study
Bitter, I., Treuer, T., Dılbaz, N., Oyffe, I., Ciorabai, E. M., Gonzalez, S. L., Ruschel, S. I., Salburg, J., & Dyachkova, Y. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.505663 · Cited by 35 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: A switch study
WANG, X., Savage, R. J., Borisov, A. S., ROSENBERG, J., Woolwine, B. J., TUCKER, M., May, R., FELDMAN, J., Nemeroff, C. B., & MILLER, A. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.03.008 · Cited by 35
Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long‐acting injection versus oral olanzapine
McDonnell, D., Kryzhanovskaya, L. A., Zhao, F., Detke, H. C., & Feldman, P. D. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1225 · Cited by 35 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
The antidepressant effects of risperidone and olanzapine in bipolar disorder.
McIntyre, R. S., Mancini, D. A., Srinivasan, J., McCann, S., Konarski, J. Z., & Kennedy, S. H. (2004) · PubMed · Cited by 35
Risperidone in the treatment of first episode psychosis.
Yap, H. L., Mahendran, R., Lim, D., Liow, P.-H., Lee, A., Phang, S., & Tiong, A. C. D. (2001) · PubMed · Cited by 35
Prospective Study to Evaluate the Efficacy of Aripiprazole as a Monotherapy in Patients with Severe Chronic Post Traumatic Stress Disorder: An Open Trial
Villarreal, G., Miller, G. A., Calais, L. A., RN, CCRC, Cañive, J. M., Lundy, S. L., Bartolomé Iglesias, S., Pickard, J., MA, et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4118 · Cited by 34 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Metabolic Syndrome in Patients Enrolled in a Clinical Trial of Aripiprazole in the Maintenance Treatment of Bipolar I Disorder
Kemp, D. E., Calabrese, J. R., Tran, Q.-V., Pikalov, A., Eudicone, J. M., & Baker, R. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05159gre · Cited by 34 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Amoxapine as an Atypical Antipsychotic: A Comparative Study Vs Risperidone
Apiquián, R., Fresán, A., Ulloa, R. E., de la Fuente‐Sandoval, C., Herrera-Estrella, M., Vazquez, A., Nicolini, H., & Kapur, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300796 · Cited by 34 · cited 1×
“05 kg (,6 wk, n = 22) [42], blonanserine 1.”
Remission in schizophrenia: one‐year Italian prospective study of risperidone long‐acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder
Rossi, A., Bagalà, A., Curatolo, V. D., Scapati, F., Bernareggi, M. M., & Giustra, M. G. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1067 · Cited by 34 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia
van Bruggen, J., TIJSSEN, J., Dingemans, P., Gersons, B. P. R., & Linszen, D. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200311000-00005 · Cited by 34 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Open-Label Trial of Aripiprazole in the Treatment of Trichotillomania
White, M. P., & Koran, L. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318221b1ba · Cited by 34 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Acute and continuation risperidone monotherapy in mania
Vieta, E., Brugué, E., Goikolea, J. M., Sánchez‐Moreno, J., Reinares, M., Comes, M., Colom, F., Martínez‐Arán, A., Benabarre, A., & Torrent, C. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.556 · Cited by 34 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS Study
Karagianis, J. L., Grossman, L. D., Landry, J., Reed, V. A., de Haan, L., Maguire, G. A., Hoffmann, V. P., & Milev, R. V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.024 · Cited by 34 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan.
Hwang, T., Lee, S.-M., Sun, H., Lin, H.-N., Tsai, S., Lee, Y.-C., & Chen, Y.-S. (2003) · PubMed · Cited by 34
Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms
Ruhrmann, S., Kissling, W., Lesch, O., Schmauß, M., Seemann, U., & Philipp, M. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.02.014 · Cited by 33 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia
Meltzer, H. Y., Bobo, W. V., Lee, M. A., Cola, P. A., & Jayathilake, K. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.02.018 · Cited by 33
Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone
Canuso, C. M., Grinspan, A., Kalali, A. H., Damaraju, C. V., Merriman, U., Alphs, L. D., & Awad, A. G. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283372977 · Cited by 33 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
Dossenbach, M. R. K., Kratky, P., Schneidman, M., Grundy, S. L., Metcalfe, S., Tollefson, G. D., & Belmaker, R. H. (2001) · PubMed · Cited by 32
Weight development in patients treated with risperidone: a 5‐year naturalistic study
Neovius, M., Eberhard, J., Lindström, E., & Levander, S. E. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00899.x · Cited by 32 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of Switching From Aripiprazole to Ziprasidone in Patients With Schizophrenia
Kim, S., Shin, I., Kim, J., Bae, K., Yang, S., & Yoon, J. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181d52b85 · Cited by 32 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study
Christensen, A. F., Poulsen, J., Nielsen, C. T., Bork, B., Christensen, A. M. B., & Christensen, M. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00736.x · Cited by 32
The Efficacy and Safety of Olanzapine for the Treatment of Geriatric Psychosis
Hwang, J., Yang, C., Lee, T., & Tsai, S. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200304000-00002 · Cited by 32 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder
Han, C., Lee, M., Pae, C., Ko, Y., Patkar, A. A., & Jung, I. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.04.017 · Cited by 31
Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia
Bushe, C., Sniadecki, J. L., Bradley, A., & Hoffmann, V. P. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108101783 · Cited by 31 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia
Buckley, P. F., Goldstein, J. M., & Emsley, R. A. (2003) · Schizophrenia Research · doi:10.1016/j.schres.2003.06.001 · Cited by 31 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Comparison of Ziprasidone and Risperidone in the Long-Term Treatment of Schizophrenia: A 44-Week, Double-Blind, Continuation Study
Addington, D. E., Labelle, A., Kulkarni, J., Johnson, G., Loebel, A. D., & Mandel, F. S. (2009) · The Canadian Journal of Psychiatry · doi:10.1177/070674370905400108 · Cited by 29 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study
Guo, X., Fang, M., Zhai, J., Wang, B., Wang, C., Hu, B., Sun, X., Lv, L., Lu, Z., Ma, C., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2242-3 · Cited by 29 · cited 1×
“38 wk, n = 162) and therefore not presented in the figure (Figure 3) [50].”
Background
Metabolic Risk with Second-Generation Antipsychotic Treatment: A Double-Blind Randomized 8-Week Trial of Risperidone and Olanzapine
Kelly, D. L., Conley, R. R., Love, R. C., Morrison, J. A., & McMahon, R. P. (2008) · Annals of Clinical Psychiatry · doi:10.1080/10401230802017050 · Cited by 28 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval
Gharabawi, G. M., Gearhart, N. C., Lasser, R. A., Mahmoud, R. A., Zhu, Y., Mannaert, E., Naessens, I., Bossie, C. A., Kujawa, M., & Simpson, G. M. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-3 · Cited by 27 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Switching to Aripiprazole in Outpatients with Schizophrenia Experiencing Insufficient Efficacy and/or Safety/Tolerability Issues with Risperidone: A Randomized, Multicentre, Open-label Study
Ryckmans, V., Kahn, J., Modell, S., Werner, C., McQuade, R., Kerselaers, W., Lissens, J., & Sanchez, R. (2009) · Pharmacopsychiatry · doi:10.1055/s-0028-1112134 · Cited by 27 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Random-Assignment, Double-Blind, Clinical Trial of Once- vs Twice-Daily Administration of Quetiapine Fumarate in Patients with Schizophrenia or Schizoaffective Disorder: A Pilot Study
Chengappa, K. R., Parepally, H., Brar, J. S., Mullen, J., Shilling, A., & Goldstein, J. M. (2003) · The Canadian Journal of Psychiatry · doi:10.1177/070674370304800307 · Cited by 27 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia
Kelly, D. L., Conley, R. R., Richardson, C., et al. (2003) · Annals of Clinical Psychiatry · doi:10.3109/10401230309085687 · Cited by 26
metan – a command for meta-analysis in Stata
Bradburn, M. J., Deeks, J. J., & Altman, D. G. (2015) · Cited by 25
Switching From Depot Antipsychotic Drugs to Olanzapine in Patients With Chronic Schizophrenia
Godleski, L., Goldsmith, L. J., Vieweg, W. V. R., Zettwoch, N. C., Stikovac, D., & Lewis, S. J. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0203 · Cited by 24 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial
Ciudad, A., Olivares, J. M., Bousoño, M., Gómez, J. C., & Álvarez, E. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.05.010 · Cited by 24
Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
Hill, A. L., Sun, B., Karagianis, J. L., Watson, S. B., & McDonnell, D. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-28 · Cited by 24
Switching elderly chronic psychotic patients to olanzapine
Barak, Y., Shamir, E. Z., Mirecki, I., Weizman, R., & Aizenberg, D. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703004048 · Cited by 24 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Double-blind Placebo-controlled Discontinuation Study of Zuclopenthixol for the Treatment of Aggressive Disruptive Behaviours in Adults with Mental Retardation – Secondary Parameter Analyses
Häßler, F., Glaser, T., Pap, A. F., Beneke, M., Diefenbacher, A., & Reis, O. (2008) · Pharmacopsychiatry · doi:10.1055/s-0028-1082072 · Cited by 24
Olanzapine in Chinese treatment‐resistant patients with schizophrenia: An open‐label, prospective trial
Chiu, N., Yang, Y. K., Chen, P. S., Chang, C., Lee, I. H., & Lee, J. (2003) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2003.01151.x · Cited by 24 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Long‐term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open‐label, prospective trial
Chawla, B., & Luxton‐Andrew, H. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.921 · Cited by 24 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Outcomes for Latin American Versus White Patients Suffering From Acute Mania in a Randomized, Double-Blind Trial Comparing Olanzapine and Haloperidol
Tamayo, J. M., Mazzotti, G., Tohen, M. F., Gattaz, W. F., Zapata, R., Castillo, J. J., Fahrer, R. D., González-Pinto, A. M., Vieta, E., Azorin, J. M., et al. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318033bd4a · Cited by 23 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia
Möller, H., Johnson, S., Mateva, T., Brecher, M., Svensson, O., Miller, F., & Meulien, D. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2d42c · Cited by 22
A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: The QUERISOLA trial
Sacchetti, E., Valsecchi, P., & Parrinello, G. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.09.011 · Cited by 22 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial
Lal, S., Thavundayil, J., Nair, N. P. V., Annable, L., Kin, N. M. K. N. Y., Gabriel, A., & Schwartz, G. J. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0631 · Cited by 21 · cited 1×
“1 (16–38 wk, n = 19) [46], lurasidone 0.”
Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine
Appelberg, B., Tuisku, K., & Joffe, G. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.06.035 · Cited by 21 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Predicted Risk of Diabetes and Coronary Heart Disease in Patients With Schizophrenia
Blonde, L., Kan, H. J., Gutterman, E. M., L'Italien, G. J., Kim, M. S., Hanssens, L., & McQuade, R. D. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0507 · Cited by 20 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study
Apiquián, R., Ulloa, E., Fresán, A., Lóyzaga, C., Nicolini, H., & Kapur, S. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00342-5 · Cited by 20 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Amisulpride Versus Olanzapine in the Treatment of Schizophrenia in Indian Patients: Randomized Controlled Trial
Bhowmick, S., Hazra, A., & Ghosh, M. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048670903487134 · Cited by 19 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Ziprasidone in Treatment-Resistant Schizophrenia
Loebel, A. D., Khanna, S., Rajadhyaksha, S., SIU, C. O., Giller, E. L., & Potkin, S. G. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0902 · Cited by 18 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Weight and Blood Pressure Change During Clozapine Treatment
Baymiller, S. P., Ball, P. M., McMahon, R. P., & Buchanan, R. W. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200207000-00003 · Cited by 18 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting
Hsieh, M., Lin, W., Chen, S., Chen, K.-C., Chen, K., Chiu, N., Huang, C., Chang, C., Lin, C., & Lai, T. (2010) · Annals of General Psychiatry · doi:10.1186/1744-859x-9-35 · Cited by 18 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Switching from Quetiapine to Ziprasidone
Karayal, O. N., Glue, P., Bachinsky, M., Stewart, M., Chappell, P. B., Kolluri, S., & Çavuş, I. (2011) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000396061.05269.c8 · Cited by 18 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Treatment with Olanzapine, Risperidone or Typical Antipsychotic Drugs in Asian Patients with Schizophrenia
Lee, C., Wu, K.-H., Habil, H., Dyachkova, Y., & Lee, P. (2006) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2006.01820.x · Cited by 17
Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial
Sacchetti, E., Panariello, A., Regini, C., & Valsecchi, P. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00225-1 · Cited by 17
Weight gain during olanzapine treatment for psychotic depression: effects of dose and age
Smith, E. G., Rothschild, A. J., Heo, M., Peasley‐Miklus, C., Caswell, M., Papademetriou, E., Flint, A. J., Mulsant, B. H., & Meyers, B. S. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f424d6 · Cited by 17 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine orally disintegrating tablets (Zyprexa ZydisR) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: An open-label prospective study
Hori, H., Ueda, N., Yoshimura, R., Yamamoto, H., Wani, K., Etoh, Y., Haraga, K., Kitahara, J., & Nakamura, J. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970903166312 · Cited by 17 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder
Hardy, T. A., Henry, R. R., FORRESTER, T. D., Kryzhanovskaya, L., Campbell, G. M., Marks, D. M., & Mudaliar, S. R. D. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01398.x · Cited by 17 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A Comparison of the Effects of Olanzapine and Risperidone Versus Placebo on Ghrelin Plasma Levels
Roerig, J. L., Steffen, K. J., Mitchell, J. E., Crosby, R. D., & Gosnell, B. A. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181613325 · Cited by 17 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine for the treatment of chronic refractory schizophrenia
Rodrı́guez-Pérez, V., López, A., Blanco, C., Peña, C., López, A., Abel, A., Gómez, Y., Ferreiro, M. J., Rego, C., López, A., et al. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00222-1 · Cited by 17 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
A prospective study of glucose homeostasis in quetiapine-treated schizophrenic patients by using the intravenous glucose tolerance test
Chen, C.-H., Lin, T., Chen, T.-T., Chen, V. C., Lin, N.-C., Shao, W., & Lu, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.01.015 · Cited by 16 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8‐week open label trial
Bobo, W. V., EPSTEIN, R. A., & Shelton, R. C. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1082 · Cited by 16 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Efficacy and Tolerability of Aripiprazole in First-Episode Drug-Naive Patients With Schizophrenia
Takahashi, H., Oshimo, T., & Ishigooka, J. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31817c6b06 · Cited by 16
Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder
Bobo, W. V., Bonaccorso, S., Jayathilake, K., & Meltzer, H. Y. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2011.07.008 · Cited by 16
Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia
Lee, K., Jeon, Y., Lee, H., & Jun, T. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1047 · Cited by 16 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia
Karagianis, J. L., Williams, R. L., Davis, L., Procyshyn, R. M., Monga, N., Hanley, J. A., Chandrasena, R. D., Thakur, A., & Dickson, R. A. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903102966 · Cited by 16 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants
Lane, H., Chang, Y., Chiu, C., Lee, S.-H., Lin, C.-Y., & Chang, W. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1685-6 · Cited by 15 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders
Parellada, E., Kouniakis, F., Šiurkutė, A., Schreiner, A., & Don, L. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328336c93f · Cited by 15 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia
Faries, D. E., Ascher‐Svanum, H., Nyhuis, A. W., & Kinon, B. J. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x297385 · Cited by 15 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Olanzapine as a possible treatment for anxiety due to vascular dementia: An open study
Moretti, R., Torre, P., Antonello, R. M., Cattaruzza, T., Cazzato, G., & Bava, A. (2004) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331750401900215 · Cited by 13 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
The effect of long-term antipsychotic treatment on the body weight of patients suffering from chronic schizophrenia: clozapine versus classical antipsychotic agents
Спивак, Б., Musin, E., Mester, R., Gonen, N., Talmon, Y., Guy, N., Roitman, S., Kupchik, M., Kotler, M., & Weizman, A. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199907000-00004 · Cited by 13 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Weight loss in persons with serious mental illness.
Daumit, G., Dickerson, F., & Appel, L. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1306994 · Cited by 12 · cited 1×
“Psychiatrists should keep in mind that switching antipsychotics requires monitoring and evaluation [51] and may benefit from concurrent non-pharmacological interventions [58,59].”
Background
The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open- label study
Herrera-Estrella, M., Apiquián, R., Fresán, A., & Sanchez-Torres, I. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-22 · Cited by 12 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Ziprasidone Outcome and Tolerability: A Practical Clinical Trial With Plasma Drug Levels
Mauri, M. C., Colasanti, A., Rossattini, M., Volonteri, L. S., Dragogna, F., Fiorentini, A., Fiorentini, A., Valli, A., & Papa, P. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-973835 · Cited by 12
Weight Changes and their Associations with Demographic and Clinical Characteristics in Risperidone Maintenance Treatment for Schizophrenia
Xiang, Y., Wang, C., Ungvari, G. S., Kreyenbuhl, J. A., Chiu, H. F. K., Lai, K. Y. C., Lee, E. H. M., Bo, Q., & Dixon, L. B. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1277178 · Cited by 11 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Belgian Schizophrenia Outcome Survey – Results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol
Peuskens, J., Gillain, B., Graeve, D. D., Vleymen, B. V., & Albert, A. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2008.11.002 · Cited by 11 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
Louzã, M. R., Elkis, Ruschel, de Oliveira, I., Bressan, R. A., Belmonte-de-Abreu, P. S., Grabowski, & Appolinário (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s20589 · Cited by 10
Olanzapine Versus Chlorpromazine in the Treatment of Schizophrenia
Dossenbach, M. R. K., Treuer, T., Kryzhanovskaya, L. A., Şaylan, M., Dominguez, S., & Huang, X. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3180ca83b1 · Cited by 10 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Effects of Orally Disintegrating Vs Regular Olanzapine Tablets on Body Weight, Eating Behavior, Glycemic and Lipid Indices, and Gastrointestinal Hormones: A Randomized, Open Comparison in Outpatients with Bipolar Depression
Bobo, W. V., EPSTEIN, R. A., & Shelton, R. C. (2011) · Annals of Clinical Psychiatry · doi:10.1177/104012371102300306 · Cited by 10 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Risperidone monotherapy in manic inpatients: An open label, multicentre trial
Forsthoff, A., Grunze, H., Seemüller, F., Stampfer, R., Dittmann, S., Amann, B. L., Schmidt, F., Schäfer, M., Hermle, L., Walden, J., et al. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970601169766 · Cited by 9 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients.
INGOLE, S. A., Belorkar, N. R., Waradkar, P., & Shrivastava, M. (2009) · PubMed · Cited by 9
Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable
Nick, B., Vauth, R., Braendle, D., Riecher‐Rössler, A., & THE SWISS StoRMi INVESTIGATORS GROU (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600633477 · Cited by 8
Metabolic Effects of Olanzapine and Quetiapine: A Six-Week Randomized, Single Blind, Controlled Study
Özgüven, H. D. (2011) · The Open Neuropsychopharmacology Journal · doi:10.2174/1876523801104010010 · Cited by 8 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Dose Pattern and Effectiveness of Paliperidone Extended-Release Tablets in Patients With Schizophrenia
Lee, J., Ahn, J., Lee, J., Kim, J., Jung, I., Lee, C., Lee, J., Lee, S.-I., & Kim, C. (2011) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3182281c05 · Cited by 6 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia
Baptista, T., Martinez, M., Lacruz, A., Arellano, A., Mendoza, S., Beaulieu, S., Hernández, L., Contreras, Q., Galeazzi, T., & Vargas, D. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.08.020 · Cited by 5 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Metabolic and Body Mass Parameters after Treatment with JNJ-37822681, A Novel Fast-Dissociating D2 Receptor Antagonist, vs Olanzapine in Patients with Schizophrenia
Daly, E. J., KENT, J. M., Janssens, L., Newcomer, J. W., Hüsken, G., Boer, P. D., Tritsmans, L., & Schmidt, M. E. (2013) · Annals of Clinical Psychiatry · doi:10.1177/104012371302500303 · Cited by 5 · cited 1×
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”

Flagged first, then by citations

Research works printed but not linked: 1

P Chue, 2005, Study of long-term quetiapine treatment, The journal of applied research, 5, 246

Sorted by citations

Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity
Hampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Avila Edwards, K. C., Eneli, I., Hamre, R., Joseph, M. M., et al. (2023) · Pediatrics · doi:10.1542/peds.2022-060640 · Cited by 1,389
Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline
Styne, D. M., Arslanian, S. A., Connor, E. L., Farooqi, I. S., Murad, M. H., Silverstein, J. H., & Yanovski, J. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2573 · Cited by 1,375
“Furthermore, clinicians should obtain a history of second-generation antipsychotics use, such as clozapine, risperidone, olan-zapine, and quetiapine, because of their association with weight gain (52, 53).”
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
“Where possible, medicines with the least risk of weight gain should be selected (Bak et al., 2014).”
Background
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
Antipsychotic medication in schizophrenia: a review
Lally, J., & MacCabe, J. H. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldv017 · Cited by 560
“The most dramatic weight gain is seen in antipsychotic naïve patients over the first 6 weeks of treatment and for the majority, those with initial weight gain did not lose that weight thereafter, even after switching to more weight-neutral antipsychotics.(14) SGAs such as aripiprazole, lurasidone and asenapine have a…”
Background

See all 490

Authors: Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M.
Affiliations: Maastricht University Medical Centre (NL)
Máxima Medisch Centrum (NL)
Corresponding author: Bak, Maarten
ORCID: Bak, Maarten
Fransen, Annemarie
Drukker, Marjan
Venue: PLoS ONE
Publisher: Public Library of Science (PLoS)
Published: 2014-04-24
Volume: 9
Issue: 4
Pages: e94112
ISSN: 1932-6203 (ISSN-L)
DOI: 10.1371/journal.pone.0094112
PMC: PMC3998960
OpenAlex: W2089001223
Cited by: 490
References: 362
Citations by year: 2026: 17 · 2025: 31 · 2024: 39 · 2023: 42 · 2022: 47 · 2021: 48 · 2020: 45 · 2019: 55 · 2018: 50 · 2017: 43 · 2016: 39 · 2015: 28 · 2014: 5
FWCI: 5.28
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: PLoS ONE (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, other-oa)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Research Publications (Maastricht University) (publishedVersion, cc-by)
RePEc: Research Papers in Economics (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Figshare (submittedVersion, cc-by)
NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
Research Publications (Maastricht University) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
Keywords: antipsychotic drugs, weight gain, body mass index, antipsychotic switching, amisulpride, aripiprazole, ziprasidone, antipsychotic-naive patients, weight loss
MeSH terms: Bipolar Disorder, Humans, Schizophrenia, Antipsychotic Agents, Weight Gain, Body Mass Index, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks